NUVL News and Press, Nuvalent Inc. From 08/10/22

Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Results PR Newswire Preliminary dose escalation data expected in second half of 2022 from the ARROS-1 study of NVL-520 for advanced ROS1 positive NSCLC an...

Nuvalent Presents New Preclinical Data Supporting Potential Best-in-Class Profile for ALK-Selective Inhibitor NVL-655 at IASLC 2022 World Conference on Lung Cancer Annual Meeting PR Newswire Trial in progress poster also to be presented for Phase 1/2 ARROS-1 study of R...

Nuvalent to Present at the Canaccord Genuity 42nd Annual Growth Conference PR Newswire CAMBRIDGE, Mass. , Aug. 3, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted...

Nuvalent Announces Leadership Promotions PR Newswire Darlene Noci , A.L.M. promoted to Chief Development Officer Benjamin Lane , Ph.D. promoted to Senior Vice President, Technical Operations CAMBRIDGE, Mass. , July 20, 2022 /PRNews...

Nuvalent to Present New NVL-655 Preclinical Data and ARROS-1 Trial in Progress Poster for NVL-520 at IASLC 2022 World Conference on Lung Cancer Annual Meeting PR Newswire Preclinical activity of ALK-selective inhibitor NVL-655 in a lorlatinib-resistant model of NSCLC w...

Nuvalent press release (NASDAQ:NUVL): Q1 GAAP EPS of -$0.36 beats by $0.04. Ended the first quarter of 2022 with $272.7 million in cash, cash equivalents, and marketable securities to support planned operations into 2024 For further details see: Nuvalent GAAP EPS of -$0.36 beats by $0.0...

Nuvalent Highlights Pipeline and Business Progress and Reports First Quarter 2022 Financial Results PR Newswire Two clinical-stage programs ongoing for potential best-in-class ROS1 and ALK-selective inhibitors On-track for selection of two additional developmen...

Nuvalent Presents New Data Demonstrating Expanded Preclinical Activity with ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022 PR Newswire NVL-520 showed strong preclinical activity against diverse ROS1 fusion partners and ...

Nuvalent to Participate in the 2022 Canaccord Genuity Horizons in Oncology Virtual Conference PR Newswire CAMBRIDGE, Mass. , April 7, 2022 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ: NUVL), a clinical stage biopharmaceutical company focused on creating ...

Nuvalent Appoints Anna Protopapas as Chair of Board of Directors PR Newswire Veteran Biotech Executive with Broad Oncology Perspective to Lead Nuvalent Board as Company Advances its Pipeline of Precisely Targeted Therapies CAMBRIDGE, Mass. , March 31,...